The efforts of establishing the pioneering software solutions ALTOmate and VARify in clinics in Europe and North America, have led to a successful third investment round for the Uppsala-based company…
VARify is the new CE/IVD-certified software for precision analysis of tumor and patient-matched normal samples. VARify offers unprecedented selectivity by reporting higher number of clinically relevant mutation calls and less…
The development of Oncodia’s CE/IVD mutation analysis software ALTOmate is complete and we are excited to announce its commercial release. ALTOmate is the diagnostic specialist’s best friend in the mutational…
During August Oncodia raised 3.3MSEK capital in a private investment round. The company was supported by the existing owners and attracted new investors. We would like to welcome Linnéa Capital…
Following the eventful nine months spent at the premises of BASE10, on 1st of April, 2020 Oncodia’s team moved to a new location. The office of Oncodia is now at…
Oncodia has acquired the assets of ExScale Biospecimen Solutions AB, including the rights to reagent kits and software CE marked for IVD for automated extraction of DNA and RNA from…
A multidisciplinary project for personalized ovarian cancer therapy selection, termed 3D-SELECT, was granted EUR €3.47 million, of which total subsidy ~ €1.82 million, on June 25, 2019. The European consortium…
Remembering the beginning of our commercialisation journey at Uppsala University Innovation (UUI), continuing through the Uppsala Innovation Centre (UIC) Business Incubator program, today we proudly announce that Oncodia is formally…
Being a medical device company, it is essential to have a Quality Management System (QMS). With the support of external consultants, Oncodia has planned and prepared its QMS according to…
Today, Oncodia finalised the grant agreement N.876876 with the European Commission’s Executive Agency for Small and Medium-sized Enterprises to receive the Horizon 2020 SME Instrument support of €50.000. Oncodia will…